Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

Sanofi-Aventis and Genzyme Finally Agree to $20.1B plus CVR Acquisition Deal

CVR payments will depend primarily on commercialization and sales milestones for MS therapy Lemtrada.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll